Exogenous estrogens, antiestrogens and lipid metabolism.
Dullaart
R P
RP
D000924:Anticholesteremic Agents / Q000627:therapeutic use; D000075202:Contraindications; D004965:Estrogen Antagonists / Q000009:adverse effects*; D015914:Estrogen Replacement Therapy / Q000009:adverse effects*; D004967:Estrogens / Q000009:adverse effects* / Q000378:metabolism; D005260:Female; D006801:Humans; D006950:Hyperlipidemia, Familial Combined / Q000150:complications; D015228:Hypertriglyceridemia / Q000097:blood / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism*; D008075:Lipoproteins, HDL / Q000097:blood / Q000187:drug effects*; D008077:Lipoproteins, LDL / Q000097:blood / Q000187:drug effects*; D008099:Liver / Q000378:metabolism; D010880:Piperidines / Q000009:adverse effects; D020849:Raloxifene Hydrochloride; D013629:Tamoxifen / Q000009:adverse effects*
D000924:Anticholesteremic Agents; D004965:Estrogen Antagonists; D004967:Estrogens; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D010880:Piperidines; D013629:Tamoxifen; D020849:Raloxifene Hydrochloride